more

DaVita (DVA)

(Delayed Data from NYSE)

$161.97 USD

+1.87 (1.17%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $161.95 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5 2

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum A VGM

Industry Rank:

Top 6% (16 out of 250)

Industry: Medical - Outpatient and Home Healthcare

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Is DaVita (DVA) Stock Undervalued Right Now?

by Zacks Equity Research Published on October 20,2023

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

DVAPositive Net Change

Quest Diagnostics (DGX) Gains From New Alliances Amid FX Woes

by Zacks Equity Research Published on October 18,2023

Quest Diagnostics' (DGX) recent acquisition of New York-Presbyterian's outreach assets adds to volume growth within Physician Lab Services.

medical

Align (ALGN) Gains From New Launches, Strategic Partnerships

by Zacks Equity Research Published on October 18,2023

Align Technology (ALGN) has well-established relationships with many DSOs, especially in the United States.

medical

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research Published on October 18,2023

Investors are optimistic about QIAGEN's (QGEN) growth in the molecular diagnostics business and the latest acquisition.

Here's Why You Should Add DaVita (DVA) Stock to Your Portfolio

by Zacks Equity Research Published on October 18,2023

DaVita's (DVA) strength in its DaVita Kidney Care raises optimism about the stock.

PetMeds (PETS) to Advance Pet Care With New Collaboration

by Zacks Equity Research Published on October 17,2023

PetMeds (PETS) is positioning itself more firmly in the field of pet health and wellness as a result of its established reputation in the pet pharmaceutical industry.

Here's Why You Should Invest in Insulet (PODD) Stock for Now

by Zacks Equity Research Published on October 16,2023

Investors are optimistic about Insulet (PODD) on continued expansion in Omnipod's market access.

Alcon (ALC) Stock Up 9.7% YTD: Will the Rally Continue?

by Zacks Equity Research Published on October 16,2023

Alcon (ALC) continues gaining from the company's diverse portfolio, incremental innovation, and new product launches.

Teleflex (TFX) Advances Urology Portfolio With New Buyout

by Zacks Equity Research Published on October 13,2023

Teleflex's (TFX) recent buyout is in line with its strategy of acquiring assets that accelerate the rate of expansion.

Walgreens Boots (WBA) Q4 Earnings Miss Estimates, Margins Down

by Zacks Equity Research Published on October 12,2023

Walgreens Boots (WBA) Q4 retail revenues are impacted by macroeconomic-driven consumer pressure and lower COVID-19 OTC test kit sales.

Here's Why You Should Hold on to Penumbra (PEN) Stock for Now

by Zacks Equity Research Published on October 12,2023

Investors are optimistic about Penumbra (PEN), driven by strong vascular and neuro businesses.

The 3 Widest Competitive Moats on Wall Street

by Andrew Rocco Published on October 11,2023

Competitive moats symbolize a company's sustainable advantage, protecting it from competitors and external threats. Three standout examples illustrate this principle vividly.

investing

Neogen's (NEOG) Q1 Earnings Miss Estimates, Margins Rise

by Zacks Equity Research Published on October 11,2023

Neogen's (NEOG) Q1 Animal Safety business experiences continued destocking, with channel inventory levels reaching multi-year lows.

Here's Why You Should Invest in Boston Scientific (BSX) Now

by Zacks Equity Research Published on October 11,2023

Investors are optimistic about Boston Scientific (BSX) on consistent growth and upbeat guidance.

Alcon (ALC) Expands Optical Care Line With Latest Launch

by Zacks Equity Research Published on October 11,2023

Alcon's (ALC) new TOTAL30 Multifocal lens outwits digital device dryness by delivering nearly 100% water at the lens's surface via a patented Water Gradient Technology.

Why DaVita HealthCare (DVA) is a Top Value Stock for the Long-Term

by Zacks Equity Research Published on October 11,2023

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

DVAPositive Net Change